Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: A randomized trial

Obstetrics and Gynecology

Volumn 105, Issue 4, 2005, Pages 811-815

  Rogovskaya, Svetlana ^a   Rivera, Roberto ^b   Grimes, David A ^b   Chen, Pai Lien ^b   Pierre Louis, Bosny ^b   Prilepskaya, Vera ^b   Kulakov, Vladimir ^b  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COPPER INTRAUTERINE DEVICE; GLYCOSYLATED HEMOGLOBIN; INSULIN; LEVONORGESTREL;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HORMONAL CONTRACEPTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTERMETHOD COMPARISON; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UTERUS;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INTRAUTERINE DEVICES, COPPER; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; TREATMENT OUTCOME;

EID: 15944422878     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000156301.11939.56     Document Type: Article

References (17)

1. World Health Organization. Improving access to quality care in family planning: medical eligibility criteria for contraceptive use. 2nd ed. Geneva (Switzerland): World Health Organization; 2000.
2. Klinke J, Toth EL. Preconception care for women with type 1 diabetes. Can Fam Physician 2003;49:769-73.
3. Chiou CF, Trussell J, Reyes E, Knight K, Wallace J, Udani J, et al. Economic analysis of contraceptives for women. Contraception 2003;68:3-10.
4. Skouby SO, Molsted-Pedersen L, Petersen KR. Contraception for women with diabetes: an update. Baillieres Clin Obstet Gynaecol 1991;5:493-503.
5. Kimmerle R, Weiss R, Berger M, Kurz KH. Effectiveness, safety, and acceptability of a copper intrauterine device (CU Safe 300) in type I diabetic women. Diabetes Care 1993;16:1227-30.
6. Kimmerle R, Heinemann L, Berger M. Intrauterine devices are safe and effective contraceptives for type 1 diabetic women. Diabetes Care 1995;18:1506-7.
7. Konje JC, Otolorin EO, Ladipo OA. Changes in carbohydrate metabolism during 30 months on Norplant. Contraception 1991;44:163-72.
8. Schroeder B, Hertweck SP, Sanfilippo JS, Foster MB. Correlation between glycemic control and menstruation in diabetic adolescents. J Reprod Med 2000;45:1-5.
9. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663-94.
10. Overall JE, Doyle SR. Estimating sample sizes for repeated measurement designs. Control Clin Trials 1994;15:100-23.
11. Diab KM, Zaki MM. Contraception in diabetic women: comparative metabolic study of Norplant, depot medroxy-progesterone acetate, low dose oral contraceptive pill and CuT380A. J Obstet Gynaecol Res 2000;26:17-26.
12. Curtis KM. Safety of implantable contraceptives for women: data from observational studies. Contraception 2002;65:85-96.
13. Klein BE, Moss SE, Klein R. Oral contraceptives in women with diabetes. Diabetes Care 1990;13:895-8.
14. Garg SK, Chase HP, Marshall G, Hoops SL, Holmes DL, Jackson WE. Oral contraceptives and renal and retinal complications in young women with insulin-dependent diabetes mellitus. JAMA 1994;271:1099-102.
15. Xiao BL, Zhou LY, Zhang XL, Jia MC, Luukkainen T, Allonen H. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception 1990;41:353-62.
16. Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv 2002;57:120-8.
17. Grigorieva V, Chen-Mok M, Tarasova M, Mikhailov A. Use of a levonorgestrel releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril 2003;79:1194-8.